Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Muscle-Pacing Technology Found to Increase Targeted Bone Volume by 30%

By LabMedica International staff writers
Posted on 02 Jul 2014
In an important advance for the health of older individuals, researchers have developed a new way to target bone growth. More...
As people age, their bones lose density, and particularly in women after the menopause, become more brittle. The new technique offers the possibility of more effective treatment than currently available. The muscle-pacing technology revealed that the lab rats in the study gained 30% of bone within the targeted areas.

The new technology was developed by researchers from the University of Liverpool’s (UK) Institute of Aging and Chronic Disease. Prof. Jonathan Jarvis, from Liverpool John Moores University designed miniature muscle pacemakers that were used in the University of Liverpool labs to generate contractions in the muscles of the legs of rats over 28 days. University of Liverpool PhD student Paula Vickerton led the research. She said, “Bone disease and fragility are affecting an increasing proportion of our population. However, existing treatments are nonspecific, affecting whole bones and not just the weaker regions.”

Using the muscle-pacing technique, the rats gained 30% of bone within the targeted areas. Ms. Vickerton’s supervisor, Dr. Nathan Jeffery, said, “This method has been shown to increase the amount of bone and raises the possibility of being developed into a treatment for people who are at risk of the many complications that weakened bone can bring.”

The study’s findings were published online and slated for the August 7, 2014 issue of the journal Proceedings of the Royal Society B: Biological Sciences.

Related Links:

University of Liverpool



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Clinical Chemistry Analyzer
Envoy 500+
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.